We have commenced the hiring process for the newly created position of Communications & Research Executive.
This new position will directly contribute to the advancement of our Strategic Plan, with a particular focus on the key aim of increasing the visibility of epilepsy and Epilepsy Ireland.
Back on World Brain Day, an important survey seeking feedback from people living with neurological conditions from across Ireland and the UK was launched. Please share your experiences!
The extended Free Travel scheme comes into effect next week - have you applied?
Learn about the study which saw us surpass the €1.5 million total investment in epilepsy research.
Read about a trial of a new device in the UK - which is showing very positive results.
Yesterday marked a significant milestone for families affected by Sodium Valproate in Ireland, with the appointment of an independent Chair for the inquiry which will investigate the historical licensing and prescribing of Sodium Valproate in Ireland.
Sodium Valproate is an effective anti-seizure medication but it can cause birth defects, neuro-developmental disorders and autism in children whose mothers take such medicines during pregnancy.
A Chairperson has been appointed for the Sodium Valproate Inquiry, as campaigned for by Epilepsy Ireland and OACS Ireland.
The Annual General Meeting of Brainwave, The Irish Epilepsy Association (trading as Epilepsy Ireland) for the year ending 31.12.23 was held on Thursday June 20th via zoom.
Important new patient information guides have been produced for males and females taking Sodium Valproate; as well as females taking Topiramate.
June 23rd is Dravet Syndrome Awareness Day.
While epilepsy is not rare, there are rare subsets of the condition, and Dravet Syndrome is one such type of rare epilepsy.
Want the latest epilepsy & Epilepsy Ireland news straight to your inbox?
Keep in touch and sign up for our monthly email update!